Ampac response to plant concerns “insufficient,” says FDA

By Gareth Macdonald

- Last updated on GMT

Related tags: Fine chemicals, Pharmaceutical drug, Food and drug administration

The US FDA has asked Ampac Fine Chemicals for a more detailed plan to fix cGMP deviations at its API plant in Rancho Cordova, California.

The current good manufacturing practices (cGMP) problems at the facility, one of several active pharmaceutical ingredient (API) plants Ampac operates​ in North America, were discovered during a Food and Drug Administration (FDA) inspection in February.

While Ampac replied to the agency in March, a letter published on the FDA's site last week​, described the response as lacking “sufficient corrective actions​.”

Foremost among the FDA’s concerns is that the fine chemicals producer has not detailed the “new procedures” it has developed to manage and quarantine rejected API batches.

This comment refers to the detection, during the inspection, of an unmarked returned drum of the oncology API temozolomide among batches of the compound that had been labeled as acceptable for release.

The FDA said that: “Your response is inadequate because you have not addressed how you will manage returned APIs​,” reminding the firm that “it is your responsibility to ensure that returned APIs are properly identified and quarantined separately from material approved for distribution​.”

Inter-batch cleaning need clarification

The FDA also highlighted cleaning procedures as an area requiring clarification, citing a January incident where cleaning was not carried out between the production of two different APIs, despite records indicating that it had been done.

In its original response to the inspection, Ampac described the event was an "isolated incident” that was not indicative of the effectiveness of its manufacturing facility audit procedures.

However, in its latest letter the FDA deemed this reaction as insufficient because the firm had not described how it will ensure cleaning is performed before batch production begins in the future.

The agency gave Ampac 15 days to respond to the letter which was issued on June 25. The Las Vegas-headquartered fine chemicals manufacturer did not respond to in-pharmatechnologist’s request for additional information on how its efforts to correct the problems are progressing.

Related news

Show more

Related products

show more

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Follow us

Products

View more

Webinars